CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 1,000 target
Drug / intervention
Blood collectionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05847855
NCT05847855N/ARecruitingHigh MomentumUpdated 3mo ago
Long Recruiting
CompareCT.gov

A Prospective Study of Plasma Cell-free DNA Fragmentomics for Early Detection of Pancreatic Neuroendocrine Tumors and Differential Diagnosis of Solid Pancreatic Tumors

Fudan University·observational·Posted May 8, 2023·Updated Mar 25, 2026

In Brief

An observational study evaluating Blood collection for Pancreatic Neuroendocrine Tumor and Solid Pancreatic Neoplasms. Currently recruiting, targeting 1,000 participants across 2 sites.

Signals

Enrolling ahead of pace

Detailed Summary

This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms
CountriesChina
CollaboratorsWest China Hospital

Timeline

N/ARecruitingOverdue
202420252026
First PostedMay 8, 2023
Enrollment StartFeb 27, 2023
Primary CompletionJun 30, 2026
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 3.1 years ago

Interventions

Blood collectionother

Blood collection for fragmentomic profiles of plasma cell-free DNA. The sub-center shall use the same blood collection consumables (EDTA anticoagulant vacutainer tubes) and blood collection volume (10ml) as the main center; plasma separation shall be completed within 2 hours after blood collection, and all operations shall comply with the study's unified SOP.